 
        
        
         
                                 
                                
                            

| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} | {[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + | 
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
 
                        
                    
| 靶点 | 
 | 
| 描述 | The mammalian protein arginine methyltransferases are a group of nine enzymes that perform NG-mono methylation-, asymmetric-, or symmetric dimethylation of arginine residues on a range of nuclear and cytoplasmic protein substrates. Protein arginine methyltransferase-5 (PRMT5) is one member of this group which catalyzes the transfer of up to two methyl groups to arginine residues, forming ω-NG-monomethyl arginine and symmetrical ω-NG-dimethyl arginine on protein substrates[3]. EPZ015666 (GSK3235025) is an orally available inhibitor of PRMT5 enzymatic activity with IC50 of 22 nM[4]. SCID mice bearing subcutaneous mantle cell lymphoma cell lines Z-138 and Maver-1 xenografts were orally given EPZ015666 on four doses: 25, 50, 100 and 200 mg/kg twice daily. Dosing at 200 mg/kg induced tumor stasis in Z-138 cells, with >93% tumor-growth inhibition (TGI) after 21 d, whereas Maver-1 cells showed >70% TGI[4]. EPZ0156660 (0 to 10 uM) dose-dependently inhibited the proliferation of multiple myeloma cell lines[5]. EPZ015666 at 5 uM also inhibited growth in patient multiple myeloma (pMM) cells cultured on a BMSCs monolayer, and also induced apoptosis of pMM cells within bone marrow mononuclear cell cultures[5]. 10 uM -EPZ treatment significantly suppressed the proliferation of several human glioblastoma cell lines: GI261, T98G, U-87 MG and A172, with loss of active S phase cells and accumulation of G2/M populations, but did not induce apoptosis[6]. | 
| 作用机制 | EPZ015666 binds in the peptide-binding site of PRMT5, including in the pocket occupied by the substrate arginine side chain. | 
| Concentration | Treated Time | Description | References | |
| CD138+ pMM cells | 5 µM | 6 days | EPZ015666 significantly inhibited the growth of CD138+ pMM cells | Leukemia. 2018 Apr;32(4):996-1002. | 
| H929 cells | 0 to 10 µM | EPZ015666 significantly inhibited the proliferation of H929 cells in a dose-dependent manner | Leukemia. 2018 Apr;32(4):996-1002. | |
| KMS11 cells | 0 to 10 µM | EPZ015666 significantly inhibited the proliferation of KMS11 cells in a dose-dependent manner | Leukemia. 2018 Apr;32(4):996-1002. | 
| Administration | Dosage | Frequency | Description | References | ||
| NOD SCID mice | GFP+-KMS11 xenograft model | Oral | 150 mg/kg | Twice daily for 21 days | EPZ015666 significantly inhibited tumor growth and prolonged survival in mice | Leukemia. 2018 Apr;32(4):996-1002. | 
| C57BL/6j mice | Pressure overload-induced heart failure model | Oral | 30 mg/kg/day | Once daily for 8 weeks | EPZ015666 significantly improved pressure overload-induced cardiac fibrosis and dysfunction, and suppressed cardiac hypertrophy and fibrosis-related gene expression. | Nat Commun. 2024 Mar 19;15(1):2472 | 
| C57BL/6J mice | Carotid artery ligation model | Oral | 50 mg/kg | Twice daily for 3 weeks | EPZ015666 markedly attenuated neointimal formation induced by carotid artery ligation in mice. | Cardiovasc Res. 2023 Oct 16;119(12):2244-2255 | 
| 计算器 | ||||
| 存储液制备 |  | 1mg | 5mg | 10mg | 
| 1 mM 5 mM 10 mM | 2.61mL 0.52mL 0.26mL | 13.04mL 2.61mL 1.30mL | 26.08mL 5.22mL 2.61mL | |
| CAS号 | 1616391-65-1 | 
| 分子式 | C20H25N5O3 | 
| 分子量 | 383.44 | 
| SMILES Code | O=C(C1=NC=NC(NC2COC2)=C1)NC[C@H](O)CN3CC4=C(C=CC=C4)CC3 | 
| MDL No. | MFCD28411588 | 
| 别名 | GSK3235025 | 
| 运输 | 蓝冰 | 
| InChI Key | ZKXZLIFRWWKZRY-KRWDZBQOSA-N | 
| Pubchem ID | 90241673 | 
| 存储条件 | In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Keep in dark place, inert atmosphere, 2-8°C | 
| 溶解方案 | DMSO: 105 mg/mL(273.83 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 
 
 
 | 
 沪公网安备 31011702889066号
			
			沪ICP备2024050318号-1
			沪公网安备 31011702889066号
			
			沪ICP备2024050318号-1